Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women
NCT ID: NCT03834571
Last Updated: 2022-06-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2022-05-31
2025-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cisplatin and Radiation Therapy in Treating Patients With HIV-Associated Locally Advanced Cervical Cancer
NCT01590017
A Safety and Efficacy of CCRT With Paclitaxel/Carboplatin as Adjuvant Therapy to Post-operative Cervical Cancer Patients
NCT00340184
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy
NCT00980954
Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
NCT00462397
Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer
NCT01295502
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
RANDOMIZED ARMS:
Arm I: Patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Participants are followed at 3, 6, 9, 12, 18 and 24 months for recurrence or progression.
Arm II: Participants undergo active monitoring at 3, 6, 9, 12, 18 and 24 months for recurrence or progression.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (standard care, carboplatin, paclitaxel)
STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.
4-8 weeks following standard care, patients receive carboplatin IV over 1 hour and paclitaxel IV over 3 hours on day 1. Courses repeat every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity.
Carboplatin
Given IV
Cisplatin
Given IV
Paclitaxel
Given IV
Radiation Therapy
Undergo radiation
Arm II (standard care, active monitoring)
STANDARD CARE: Patients receive cisplatin IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36. Patients also undergo radiation therapy over 2-5 fractions 5 days a week for up to 8 weeks in the absence if disease progression or unacceptable toxicity. 4-8 weeks following standard of care.
4-8 weeks following standard care, patients undergo active monitoring at 3, 6, 9, 12, 18 and 24 months.
Cisplatin
Given IV
Patient Monitoring
Undergo active monitoring
Radiation Therapy
Undergo radiation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Carboplatin
Given IV
Cisplatin
Given IV
Paclitaxel
Given IV
Patient Monitoring
Undergo active monitoring
Radiation Therapy
Undergo radiation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HIV positive. Documentation of HIV-1 infection by means of any one of the following:
* Documentation of receipt of ART by a licensed health care provider (documentation may be a record of an ART prescription in the participant's medical record, a written prescription in the name of the participant for ART, or pill bottles for ART with a label showing the participant's name)
* HIV-1 ribonucleic acid (RNA) detection by a licensed HIV-1 RNA assay demonstrating \>1000 RNA copies/mL confirmed by a licensed screening antibody and/or HIV antibody antigen combination assay
* Any licensed HIV screening antibody and/or HIV antibody/antigen combination assay confirmed by a second licensed HIV assay such as a HIV-1 Western blot confirmation or HIV rapid multispot antibody differentiation assay.
* Note: The term "licensed" refers to a kit that has been certified or licensed by an oversight body within the participating country and validated internally. WHO (World Health Organization) and CDC (Centers for Disease Control and Prevention) guidelines mandate that confirmation of the initial test result must use a test that is different from the one used for the initial assessment. A reactive initial rapid test should be confirmed by either another type of rapid assay or an E/CIA that is based on a different antigen preparation and/or different test principle (e.g., indirect versus competitive), or a Western blot or a plasma HIV-1 RNA viral load.
* Hemoglobin \>= 10 g/dL (6.2 mmol/L) (participants receiving transfusion are permitted) (within 4 weeks prior to enrollment)
* Leukocytes: \>= 3,000/mm\^3 (3.0 x 10\^9/L) (within 4 weeks prior to enrollment)
* Absolute neutrophil count: \>= 1,500/mm\^3 (1.5 x 10\^9/L) (within 4 weeks prior to enrollment)
* Platelets: \>= 100,000/mm\^3 (100 x 10\^9/L) (within 4 weeks prior to enrollment)
* CD4 T-cell count a minimum of 200 cells/uL (within 4 weeks prior to enrollment)
* Total bilirubin =\< 2 x institutional upper limit of normal (ULN) unless related to antiretroviral use (e.g., atazanavir or indinavir), then the direct bilirubin must be =\< 2 x ULN (within 4 weeks prior to enrollment)
* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]): =\< 3 x ULN (within 4 weeks prior to enrollment)
* Creatinine levels within normal institutional limits or, creatinine clearance \>= 60 mL/min/1.73 m\^2 (1.00 mL/s) calculated by the Cockcroft-Gault equation for women for participants with creatinine levels above institutional normal (within 4 weeks prior to enrollment)
* All participants must be prescribed combination antiretroviral therapy with the goal of virological suppression using an acceptable regimen that adheres to national guidelines for treatment of HIV infection. If on a ritonavir- or cobicistat-based regimen, the participant must be switched to a non-ritonavir/ cobicistat-based regimen at least 7 days before treatment enrollment. Participants not on ART must start an acceptable regimen at least 7 days before treatment enrollment.
* In the investigator's opinion the participant is suitable for treatment with radical intent using concurrent chemotherapy and pelvic radiation followed by adjuvant chemotherapy
* Participants of childbearing potential, defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months), must have a negative urine or serum pregnancy test within 3 weeks prior to enrollment and agree to use an effective form of contraception (e.g., barrier contraception, highly effective hormonal contraception) for the duration of treatment and for 6 weeks after stopping treatment
* Life expectancy of greater than 6 months
Exclusion Criteria
* Participants who are receiving any other investigational agents
* Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicity \> grade 1).
* Participants who have undergone hysterectomy including supracervical hysterectomy
* Acute active (such as tuberculosis or malaria), serious, uncontrolled infection
* Prior invasive malignancy requiring systemic chemotherapy diagnosed within the past 24 months (other than LACC)
* A medical or psychiatric illness that precludes ability to give informed consent or is likely to interfere with the ability to comply with the protocol stipulations
* Participants with circumstances that will not permit completion of the study or required follow-up. For instance, if travel to and from treatment site is an issue
* Participants with carcinoma of the cervical stump
* Participants with history of cardiovascular disease manifested as:
* History of myocardial infarction
* Unstable angina
* Currently taking medication for treatment of angina
* History of coronary artery bypass surgery
* New York Heart Association class 3 or 4 heart failure
* Participants with enlarged para-aortic lymph node involvement above L3 on imaging that are suspicious for metastasis
* History of allergic reactions attributed to compounds of similar chemical or biological composition to study drugs (cisplatin, carboplatin, and paclitaxel)
* Participants who are breastfeeding a child. Cisplatin is known to be excreted in human milk.
Eligibility for Randomization
* Participants must have organ and marrow function within the following parameters within 4-8 weeks post CDDP/RT to be eligible for randomization
* Absolute neutrophil count: ≥1,500/mm3 (1.5 x 109/L)
* Platelets: ≥ 100,000/mm3 (100 x 109/L)
* CD4 T-cell \> 100 cells/µL
* HIV viral load \< 400 copies/mL
* ECOG performance status ≤ 2 (Karnofsky ≥ 50%).
* Successful completion of CDDP/RT, defined as receiving 4-6 cycles of cisplatin and completion of the equivalent dose per fraction of \>78 Gy to Point A.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
The Emmes Company, LLC
INDUSTRY
University of Stellenbosch
OTHER
University of Arkansas
OTHER
AIDS Malignancy Consortium
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ntokozo Ndlovu
Role: PRINCIPAL_INVESTIGATOR
Parirenyatwa Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stellenbosch University
Cape Town, , South Africa
University of Witwatersrand
Johannesburg, , South Africa
Parirenyatwa Hospital
Harare, , Zimbabwe
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2018-01903
Identifier Type: REGISTRY
Identifier Source: secondary_id
AMC-102
Identifier Type: OTHER
Identifier Source: secondary_id
AMC-102
Identifier Type: OTHER
Identifier Source: secondary_id
AMC-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.